A placebo-controlled Phase 2 trial of oral CR845 in patients with non-hemodialysis stage III-V chronic kidney disease associated pruritus (CKD-aP)

Trial Profile

A placebo-controlled Phase 2 trial of oral CR845 in patients with non-hemodialysis stage III-V chronic kidney disease associated pruritus (CKD-aP)

Planning
Phase of Trial: Phase II

Latest Information Update: 30 Oct 2017

At a glance

  • Drugs Difelikefalin (Primary)
  • Indications Pruritus
  • Focus Therapeutic Use
  • Sponsors Cara Therapeutics
  • Most Recent Events

    • 30 Oct 2017 New trial record
    • 25 Oct 2017 According to a Cara Therapeutics media release, the company plans to initiate this trial in the first quarter of 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top